Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
Remo Panaccione(University of Calgary), Leonardo Salese(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna), Mary Ellen Frustaci(Johnson & Johnson (United States)), Tadakazu Hisamatsu(Kyorin University), Jane M. Andrews(Health Net), Julián Panés(Hospital Clínic de Barcelona), Silvio Danese(IRCCS Ospedale San Raffaele), Rian Van Rampelbergh(Janssen (Belgium)), David T. Rubin(University of California System), Geert D’Haens(Amsterdam University Medical Centers), Zijiang Yang(Xi'an Jiaotong University), Natalie A. Terry(Janssen (United States)), Aparna Sahoo(Otsuka (United States)), Marion Vetter(Janssen (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Jacqueline Yee(Johnson & Johnson (United States)), Brian G. Feagan, Anita Afzali(University of Cincinnati Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Chenglong Han(Janssen (United States)), Kitty Y. Wan(Johnson & Johnson (Switzerland))
Cited by 44
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k